Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Summary

This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be treated with SABR 20Gy in 1# followed by atezolizumab or SABR 24Gy in 3# followed by atezolizumab.

Timeline

Start

2018-08-01

Primary completion

2023-06-22

Completion

2023-06-22

Drugs

Indications